Growth in literacy and cognition in bilingual children at risk or not at risk for reading disabilities.

An Investigation of the Multiple Correlations between Visual-Perception Skills and the Indices of Wechsler Intelligence Scale for Children with Learning Disabilities

“…The findings of the present study are in line with those of Seidman, Biederman, Doyle, and Faraone (2001), Semrud-Clikeman et al (1992), Swanson et al (2006), and Swanson and Jerman (2007). Swanson, Ashbaker, andLee (2000 qtd.…”

“…A number of researches including Seidman, Biderman, Doyle & Faran (2001), Seidman (2006), Swanson et al (2006), and Swanson and Jerman (2007) have shown that children with learning disabilities have lower performance in comparison with normal children in achievement, learning, and attention tests. Other studies have also pointed out that neurological deficiencies such as performance and attention disorders in pre-primary school children continue to exist at later ages and challenge the children in doing homework and personal tasks.…”

Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas

“…Tumour stabilization has frequently been observed in patients with GEP tumours treated with somatostatin analogues, and has also been reported in various series of progressive neuroendocrine tumours [16,22,23,24,25]. Indeed, a better and longer sustained response has been achieved in slow-growing tumours, with a 76% response at a median time of 11 months in 1 study [23], a 86% response at a median time of 25 months in another [16] and a 38% response at a median time of 50 months in another [15]. Moreover, somatostatin treatment has always been reported to be effective in decreasing the rate of tumour growth, although it was less effective with fast-growing tumours and not sufficient to inhibit aggressive tumour behaviour [15, 16, 23].…”

“…In controlled studies, this effect was focused primarily on patients with functioning GEP tumours, and was reported to be a very rare event (about 5% of cases) regardless of the dosage or formulation of the drug [16,17,18,19,20,21,22,23]. Tumour stabilization has frequently been observed in patients with GEP tumours treated with somatostatin analogues, and has also been reported in various series of progressive neuroendocrine tumours [16,22,23,24,25]. Indeed, a better and longer sustained response has been achieved in slow-growing tumours, with a 76% response at a median time of 11 months in 1 study [23], a 86% response at a median time of 25 months in another [16] and a 38% response at a median time of 50 months in another [15].…”

“…Indeed, a better and longer sustained response has been achieved in slow-growing tumours, with a 76% response at a median time of 11 months in 1 study [23], a 86% response at a median time of 25 months in another [16] and a 38% response at a median time of 50 months in another [15]. Moreover, somatostatin treatment has always been reported to be effective in decreasing the rate of tumour growth, although it was less effective with fast-growing tumours and not sufficient to inhibit aggressive tumour behaviour [15, 16, 23]. Little information is available on the correlation of growth response with SSTR expression in the tumour.…”